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p53-Dependent and Cell Specific Epigenetic Regulation
of the Polo-like kinases under Oxidative Stress
Alejandra Ward, John W. Hudson*
Department of Biology, University of Windsor, Windsor, Ontario, Canada

Abstract
The polo-like kinase (PLKs) family, consisting of five known members, are key regulators of important cell cycle processes,
which include mitotic entry, centrosome duplication, spindle assembly, and cytokinesis. The PLKs have been implicated in a
variety of cancers, such as hepatocellular carcinoma (HCC), with PLK1 typically overexpressed and PLKs 2–5 often
downregulated. Altered expression of the PLKs in malignancy is often correlated with aberrant promoter methylation.
Epigenetic marks are dynamic and can be modified in response to external environmental stimuli. The aim of our study was
to determine if oxidative stress, a common feature of solid tumours, would induce changes to the promoter methylation of
the PLKs resulting in changes in expression. We examined the promoter methylation status via MSP and subsequent
expression levels of the PLK family members under exposure to hypoxic conditions or reactive oxygen species (ROS).
Interestingly, murine embryonic fibroblasts exposed to hypoxia and ROS displayed significant hypermethylation of Plk1 and
Plk4 promoter regions post treatment. Corresponding proteins were also depleted by 40% after treatment. We also
examined the HCC-derived cell lines HepG2 and Hep3B and found that for PLK1 and PLK4, the increase in hypermethylation
was correlated with the presence of functional p53. In p53 wild-type cells, HepG2, both PLK1 and PLK4 were repressed with
treatment, while in the p53 null cell line, Hep3B, PLK4 protein was elevated in the presence of hypoxia and ROS. This was
also the case for ROS-treated, p53 null, osteosarcoma cells, Saos-2, where the PLK4 promoter became hypomethylated and
protein levels were elevated. Our data supports a model in which the PLKs are susceptible to epigenetic changes induced by
microenvironmental cues and these modifications may be p53-dependent. This has important implications in HCC and
other cancers, where epigenetic alterations of the PLKs could contribute to tumourigenesis and disease progression.
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these proteins is essential for the maintenance of genomic integrity
and the prevention of genomic instability. Therefore, the
underlying question is what is prompting the aberrant epigenetic
regulation of the polo-like kinases in a variety of cancer types?
It has been established that the microenvironment plays a
significant role in the initiation and progression of tumourigenesis.
The cellular microenvironment provides a platform from which
bidirectional molecular cues can be exchanged. This topographical information can direct cellular phenomena which include
growth, cellular differentiation, and division. The aberrant
alterations in the microenvironment can confer tumourigenicity
through direct genetic mutations, but more so via epigenetic
plasticity [15,16]. Oxidative stress, in the form of reactive oxygen
species (ROS) and hypoxia, are components of the tumour
microenvironment, and have been shown to be causative agents of
abnormal, epigenetically-induced gene expressions in a variety of
tumour types [17–19]. Studies have also revealed that several
tumour suppressors and cell cycle regulators such as p14ARF,
p16INK4a, and BRCA1 are susceptible to epigenetic silencing
through DNA hypermethylation or histone modification in the
presence of oxidative stress [19,20]. The purpose of this study was
to examine the susceptibility of individual PLK regulation through
epigenetic modifications in response to oxidative stress in the form
of either ROS or hypoxia. Here we have determined that the polo-

Introduction
The polo-like kinases (PLKs) have been implicated in a variety of
solid and hematopoietic tumours, which include B-cell lymphoma,
hepatocellular carcinoma (HCC), head and neck squamous
carcinoma, colorectal cancers, and most recently gallbladder
cancer, just to name a few [1–5]. Moreover, their deregulation is
often associated clinically with poor prognosis, such as the case of
PLK1 overexpression in non-small cell lung carcinoma and head
and neck squamous carcinoma, or downregulation of Plk4 in
HCC [3,6,7]. Recently, we and others, have determined that the
polo-like kinases, which are cell cycle regulated serine/threonine
kinases, are susceptible to aberrant DNA methylation in many of
the tumour types described above [1,8–10]. Aberrant promoter
methylation of PLK1-4 have been implicated in hepatocellular
carcinoma [9,10], while PLK2 promoter hypermethylation has
been detected in hematologic malignancies such as acute myeloid
leukemia and B-cell lymphoma, as well as in ovarian cancers
[1,8,11]. Interestingly, the recently discovered PLK5, has tumour
suppressor properties, and it is often hypermethylated in
glioblastoma [12]. Given that these kinases, which are highly
conserved among species, play crucial roles in important cell cycle
events such as spindle pole assembly, the DNA damage response,
G2/M transitions, and cytokinesis [6,13,14], proper regulation of
PLOS ONE | www.plosone.org
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Previous research has shown that p53 is both necessary and
sufficient in transcriptionally repressing Plk1 [26]. In a regenerating liver model, Plk4 heterozygosity resulted in decreased p53
protein levels and activity compared to the wild-type model as
evidenced by decreased p21 levels and phosphorylated Ser15 on
p53 [2], suggesting that Plk4 heterozygosity is insufficient for
proper p53 activation. This also suggests a model in which Plk1
expression in wild-type MEFs exposed to hypoxia is in part
regulated by promoter methylation, resulting in repression of
transcription and lower protein levels. The different response for
Plk1 in Plk4+/2 MEFs, is likely related to the fact that Plk4+/2
MEFs display increased genomic instability along with a lack of
active p53 during stress [2]. Thus, the normal regulatory
mechanisms necessary to down-regulate Plk1 protein levels are,
in part, absent. This combination of lower Plk4 and increased Plk1
likely results in promoting the cellular transition through G2/M,
and further propagating genomic instability and aneuploidy
resulting in DNA damage caused by Plk4 haploinsufficiency [2],
a contributing factor to tumourigenesis. It also further suggests that
Plk4 needs to be at normal levels in order to maintain appropriate
Plk1 levels.

like kinases are indeed epigenetically modified in the presence of
oxidative stress, though in a cell type-dependent and p53dependent manner. Furthermore, we have determined that Plk4
heterozygosity may play a role in the epigenetic regulation of Plk1
in response to oxidative stress.

Results and Discussion
Plks are subject to epigenetic modification under hypoxic
conditions in normal and tumour-derived cells in vitro
Hypoxia has been established as a characteristic of the solid
tumour microenvironment and has been shown to promote cell
migration and cell transformation [21,22]. The primary mediator
of the cellular response to hypoxia is hypoxia inducible factor 1a
(Hif1a) which is responsible for the transcriptional regulation of
several key genes, such as vascular endothelial growth factor
(VEGF) [23] and metabolic components such as nitric oxide (NO)
which are important for the cellular adaptation to a hypoxic
environment [24]. More recently, Hif1a has been shown to
indirectly modify epigenetic marks on histone tails leading to
varying levels of transcriptional activation and repression through
histone deactylatase (HDAC) recruitment and modification of the
H3K9 methylation marks [25].
We have previously shown that Plk4 heterozygosity increases the
susceptibility of Plk4 promoter methylation in an in vivo murine
HCC model [10], therefore we wanted to determine whether Plk4
heterozygosity impacted Plk promoter methylation under oxidative
stress. First, wild type (Plk4+/+) and heterozygous (Plk4+/2) murine
embryonic fibroblasts (MEFs) were cultured in a hypoxia chamber
flooded with 2% oxygen and incubated for 18 hours in order to
determine whether the exposure of cells to hypoxia results in the
modification of Plk gene expression through epigenetic means.
After the treatment, methylation specific PCR (MSP) was
performed in order to examine the methylation status of the Plks.
We did observed Plk4 promoter methylation upon hypoxia
treatment, regardless of genotype (Fig. 1a). Furthermore, corresponding Plk4 transcripts were decreased by approximately 12fold compared to the untreated in both Plk4+/+ and Plk4+/2 MEFs
under hypoxic conditions (Fig. 1b). Interestingly, Plk4 transcript
and protein levels post hypoxia treatment in the Plk4+/+ MEFs
were comparable to the levels normally found in Plk4 heterozygous
cells. Moreover, treated Plk4 heterozygous MEFs displayed even
further depleted Plk4 protein levels by approximately 10%
compared to the untreated counterpart (Fig. 1c,d). This suggests
that the Plk4 promoter region may be targeted for methylation
under hypoxic conditions. Next, we sought to determine whether
the modification to the epigenetic marks that we observed were
specific to Plk4, or if the other Plks were also undergoing a similar
response. Interestingly, hypoxia treatment of wild-type MEFs
resulted in hypermethylation of the Plk1 promoter region (Fig. 1a)
with a corresponding seven-fold decrease in transcript levels
(Fig. 1e) and a 20% decrease in protein levels when compared to
non-treated controls (Fig. 1f). Considering that Plk1 was methylated prior to treatment in Plk4+/2 MEFs, it was not surprising to
see that there was no change in the methylation status of Plk1
promoter with hypoxia (Fig. 1a). In contrast, there was a moderate
increase in the corresponding Plk1 transcripts (Fig. 1e). Examination of Plk1 protein levels in untreated Plk4+/2 MEFs revealed
almost 40% higher Plk1 levels compared to the wild type cells
prior to treatment (Fig. 1f). Moreover, post-treatment, Plk4+/2
MEFs showed approximately a 10% increase in Plk1 protein levels
compared to the untreated (Fig. 1f). As a positive control, Hif1a
transcript levels were assessed post treatment to ensure the cells
were responding to hypoxic conditions (Fig. 1g).
PLOS ONE | www.plosone.org

ROS-induced epigenetic downregulation of the Plks in
MEFs
Oxidative stress in the microenvironment is not limited to
hypoxic conditions. Oxidative stress can also be caused by an
increase in free radicals producing reactive oxygen species (ROS).
Furthermore, ROS have been shown to promote tumourigenesis
through several biological processes which include cell proliferation, metastasis, and evasion of apoptosis [27]. Exposure of cells to
high levels of ROS have also been implicated in the hypermethylation of tumour suppressor genes such as runt-related transcription factor 3 (RUNX3) [28]. Moreover, ROS exposure, as a result
of hydrogen peroxide treatment, has been shown to recruit DNA
methyltransferases (DNMT) complexes to areas in the genome
that are CG-rich, which could include the CpG islands upstream
of the Plk promoter regions [29]. Additionally, in our previous
work, we demonstrated that wild type MEFs that were chronically
exposed to ethanol (EtOH) treatment, displayed a hypermethylated Plk4 promoter region resulting in a phenotype that resembles
that seen in Plk4+/2 cells with multi-nucleation and multiplecentrosome formation [10]. Inherent to ethanol metabolism is the
production of high levels of ROS [30] therefore, suggesting that
ROS may also impact Plk promoter methylation. In order to
examine whether Plk1 and Plk4 epigenetic marks were susceptible
to modification as a result of high levels of ROS, we subjected
Plk4+/+ and Plk4+/2 MEFs to reactive oxygen species (ROS) by
exposing them to hydrogen peroxide (H2O2) at a 200 um dose for
a period of 18 hours. This level of ROS is known to induce DNA
damage and p53 activity [31]. Methylation specific PCR (MSP)
revealed that the Plk4 promoter became hypermethylated in the
presence of ROS (Fig. 2a). Both Plk4+/+ and Plk4+/2 MEFs
displayed a decrease in Plk4 transcripts of more than 10-fold
(Fig. 2b) and subsequent Western blot analysis revealed a
significant decrease in Plk4 protein in both MEF genotypes by
approximately 50% (p,0.05) relative to the untreated cells
(Fig. 2c,d). These results are similar to what we observed under
hypoxic conditions, and suggest that as part of the stress and DNA
damage response, Plk1 and Plk4 may normally become downregulated via promoter methylation likely in order to arrest cell
division. It is noted previous work by Ko et al. revealed that low
levels of Plk4 results in a delay in cell cycle progression [2], and we
have shown that lower levels of Plk4 results in cells aggregating at
the G2/M transition of the cell cycle [32].
2
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Figure 1. Aberrant methylation of plk1 and plk4 promoter regions in MEFs under hypoxic stress. (a) DNA extracted from mouse
embryonic fibroblasts grown under hypoxic conditions was bisulfite treated and then assessed for promoter methylation of Plk1 and Plk4 using
methylation specific PCR; U = unmethylated, M = methylated. Fully methylated NIH 3T3 DNA was used as a positive control (+M), no template was
added to the negative control (2M). (b) Plk4 transcripts were assessed using qPCR. Transcript levels were normalized to the wild type untreated
sample. All qPCR data is representative of the mean value of three independent experiments and error bars represent +/2 SD. (c) Western blot
analysis to examine protein levels of Plk1 and Plk4 post hypoxic treatment. (2) represents the lysates from untreated cells, (+) lysates from cells were
grown in the presence of hypoxia. (d) Densitometric analysis normalized to the levels of the wild-type untreated cells. Error bars represent +/2 SD
from three independent experiments. (e) The fold change of plk1 transcripts normalized to the respective untreated transcripts. (f) The percent of
Plk1 protein expression relative to the untreated wild-type cells. * denotes significance with p,0.05. (g) RNA extracted from MEFs along with realtime PCR was used to determine Hif1a transcripts post hypoxia treatment.
doi:10.1371/journal.pone.0087918.g001

Plk1 promoter methylation and levels in Plk4+/+ MEFs were
responsive to increased ROS in a similar manner to that seen with
hypoxia, in which Plk1 was downregulated (Fig. 2a). Plk1
transcripts were decreased by approximately 12-fold, which was
reflective of the promoter hypermethylation (Fig. 2e). This was
correlated with visibly reduced protein levels post ROS exposure
by almost 40% (Fig. 2c,f). Although there appeared to be no visible
change at the promoter region via MSP analysis, Plk1 transcripts
were elevated in the heterozygous MEFs in the presence of ROS
with transcripts almost 15-fold higher compared to the untreated
(Fig. 2a,e). Moreover, Plk1 protein expression levels were also 10%
higher in ROS-treated heterozygous MEFs compared to the
untreated counterparts and 100% higher compared to the treated
wild-type MEFs (p,0.05) (Fig. 2c,f). In contrast to Plk4 and Plk1,
Plk2 promoter methylation as well as Plk2 and Plk3 protein levels
displayed no detectable changes in either cell type in response to
hypoxia and upon exposure to reactive oxygen species (Figure

PLOS ONE | www.plosone.org

S1a,b). Note that, we did not examine Plk3 promoter methylation
as the gene in mouse lacks CpG islands.
The experimental results observed for Plk1 and Plk4 epigenetic
regulation in MEFs as a response to ROS were similar to those
obtained under hypoxic conditions, suggesting that an adequate
response to stress and the DNA damage may be impaired in
Plk4+/2 MEFs and that lower Plk4 protein levels have an indirect
impact on the epigenetic regulation of Plk1. This model is
supported by the observations that upon DNA damage, p53 is
activated and subsequently represses Plk1 [33,34]. Previous work
has determined that p53 interacts with and is a substrate of Plk4;
and in the Plk4+/2 mouse model, partial hepatectomy failed to
activate p53 within the first 24 hours post-surgery, unlike the wildtype counterparts which displayed p53 activation almost immediately [2,35].
Given these observations, it was therefore of interest to
determine whether p53 was activated in Plk4+/2 MEFs post
ROS treatment. We performed an ELISA-based p53 activity assay
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Figure 2. Modification of plk1 and plk4 epigenetic marks with ROS exposure in MEFs. (a) MSP analysis shows the promoter methylation of
plk1 and plk4 pre- and post-ROS treatment; U = unmethylated, M = methylated. Fully methylated NIH 3T3 DNA was used as a positive control (+M), no
template was added to the negative control (2M). (b) Plk4 transcript levels determined by qPCR. All transcripts were normalized to the wild type
untreated control. All qPCR data is representative of the mean value of three independent experiments and error bars represent +/2 SD. (c) Plk1 and
plk4 protein levels examined via Western blot analysis, actin was used as a loading control. (2) represents the lysates from untreated cells, (+) lysates
from cells grown in the presence of ROS (d) Plk4 protein expression levels determined by densitometry. All densitometry data is representative of
three independent experiments and the error bars represent +/2 SD. * denotes significance with a p,0.05. (e) Plk1 transcripts of cells treated with
ROS, the transcripts were normalized to the respective untreated samples. (f) The relative plk1 protein levels post treatment was normalized to the
wild-type untreated samples. Levels determined by densitometric analysis of Western blot images. (g) An ELISA-based p53 activity assay. Relative
activity was determined by normalizing values to the untreated samples. This data represents the mean value obtained over three independent
experiments and error bars denote the +/2 SD. (h) p53 protein levels in MEFs post treatment as determined by Western blot analysis. (i) Densitometry
was performed on three independent experiments and all data has been normalized to the respective untreated. The mean expression is presented
with error bars denoting +/2 SD. * denotes significance with a p,0.05.
doi:10.1371/journal.pone.0087918.g002

with MEF nuclear extracts post H2O2 treatment. Plk4+/+ cells had
an increase in p53 protein levels by almost 50% and an increase in
p53 activity by almost 6-fold relative to the untreated cells (Fig. 2g–
i). Unexpectedly, in Plk4+/2 MEFs, p53 activity was not elevated,
but was comparable to the untreated counterparts (Fig. 2g). This
corresponded to the lack of a significant change in p53 protein
levels for the Plk4+/2 MEFs (Fig. 2h,i). Our observations suggest
that Plk4 heterozygosity and the subsequent low Plk4 protein levels
are insufficient to activate p53 during genotoxic stress caused by
ROS, resulting in an upregulation in the pro-mitotic protein, Plk1.
Interestingly, in our previous examination of HCC in Plk4+/2
mice, we also observed elevated Plk1 protein in tumours, but not
in normal liver tissue [10]. Human studies have found that loss of
heterozygosity for PLK4 occurs in 45–60% of HCC cases
examined together with an increase in Plk1 protein levels [2,9].

PLOS ONE | www.plosone.org

PLK4 LOH may be an early event in the progression to
carcinogenesis. Here we show that a combinatorial effect of Plk4
heterozygosity, together with micro-environmental stressors such
as hypoxia and ROS, result in the upregulation of Plk1.

Promoter methylation of the Plks in HCC tumour cells
Li et al. 2005 demonstrated that PLK4 mRNA is regulated in a
p53-dependent manner in lung carcinoma cells and osteosarcomaderived cells exposed to etoposide [36]. The levels of PLK4
transcripts were most affected at 6 and 24 hours post treatment
[36]. Thus, p53 plays a role in the transcriptional downregulation
of PLK4 through histone deacetylation upon exposure to DNA
damaging agents [36]. Recently, Nakamura et al. also showed that
sustained genotoxic stress via etoposide and UV resulted in the
attenuation of PLK4 in a p53-dependent manner [37]. In
4
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addition, p53 is known to be an important player in the epigenetic
downregulation of another tumour suppressor, ras-associated
domain family 1 (RASSF1A), by directly binding to the promoter
of RASSF1A and recruiting DNA methyltransferase 1(DNMT1)
along with accessory proteins to the promoter region [38].
Moreover, p53 interacts and cooperate with DNMT1 in the
methylation of the PLK4 target, CDC25C, in the presence of
DNA damage [39] and also interacts with DNMT3a, which is
responsible for de novo methylation [40]. This suggests that p53
likely also regulates the Plks through an epigenetic mechanism. We
were therefore interested in determining whether the promoter
methylation of the Plks, which we observed in MEFs under
hypoxia and ROS treatment, was dependent on the presence or
absence of p53. We employed the hepatocellular carcinoma
(HCC) derived cell lines, HepG2 and Hep3B to answer this
question. Both HepG2 cells and Hep3B cells exhibited an increase
in PLK4 promoter methylation post hypoxia (Fig. 3a). In the case
of HepG2 cells there was an increase in the detectable level of
methylation accompanied with a corresponding 2-fold decrease in
PLK4 transcripts (Fig. 3b) compared to the untreated as well as a
5% decrease in protein levels (Fig. 3c,d). For Hep3B cells, under
hypoxic conditions, the increase in promoter methylation did not
translate into significant changes at transcript and proteins levels
(Fig. 3c,d). In this case, protein levels of PLK4 did not show a
significant difference, although transcript levels were slightly
decreased (Fig. 3c,d). As HepG2 cells contain a functional p53
whereas as Hep3B cells lack a functional p53 [41], these results
once again suggest the involvement of p53 in the epigenetic
regulation of PLK4.
Likewise, for PLK1, the change in methylation status was similar
to that seen with hypoxia treatment in MEFs. Before treatment,
HepG2 cells displayed some methylation for the PLK1 promoter
(Fig. 3a). Post hypoxia, the PLK1 promoter region became
hypermethylated (Fig. 3a). In addition, transcript levels were
decreased by almost 2.5-fold (Fig. 3e) and accompanied by a slight
decrease in protein levels (Fig. 3c). Hep3B cells, on the other hand,
showed no distinct change in the methylation status of PLK1
promoter region compared to the untreated (Fig. 3a). Moreover,
PLK1 transcript and protein levels in treated Hep3B cells were not
significantly impacted by hypoxia treatment (Fig. 3c,e).
Human PLK3, unlike its murine homolog has two CpG islands
in its promoter region. We used two sets of primers in order to
assay for any changes in methylation status for PLK3. With both,
MSP published primers based on the first 200 base pairs of the
upstream CpG island [1] and an additional set of MSP primers
downstream, we detected no overt change in promoter methylation for PLK3 in either HepG2 or Hep3B cells (Fig. 3a). This
suggests that the regulation of PLK3 under hypoxic conditions is
not p53 dependent and is likely not regulated by an epigenetic
mechanism in this context.
Likewise, for PLK2, there was no dramatic change in promoter
methylation, for either HepG2 and Hep3B cell lines. This
indicates that PLK2 and PLK3 do not undergo aberrant changes
to their promoter methylation in response to hypoxia.
As an experimental control, we assessed the transcript levels of
HIF1a to determine whether these cells were responding to
hypoxic stress under the same hypoxic conditions as used with the
MEFs. With hypoxia, HIF1a transcripts were elevated by more
than 1.5 times in both cell lines (Fig. 1g), indicating that the cells
were indeed responding to low oxygen levels and the change in
HIF1a transcript levels were similar to previously reported hypoxia
treatments in HCC cells [42].

PLOS ONE | www.plosone.org

Plk promoter methylation in HCC with ROS treatment
HepG2 and Hep3B were cultured in the presence of hydrogen
peroxide at a concentration of 200 um and activation of p53 by
ROS was confirmed via an ELISA-based p53 activity assay and
Western blot analysis. As expected, we found a 6-fold increase in
p53 activity in HepG2 cells in the presence of ROS, while no
change in activity was detected for Hep3B (Fig. 4a). The increase
in activity also corresponded to an increase in p53 protein levels in
HepG2 cells, while in agreement with Hep3B p53 status, no p53
protein was detected in Hep3B cells (Figure S1c). PLK1 became
hypermethylated in HepG2 post ROS exposure, while in Hep3B
the level of detectable methylation decreased in comparison to that
initially present in untreated cells (Fig. 4b). Subsequent examination of the transcript and protein expression for PLK1 were
correlated with their respective promoter methylation status.
Specifically, in HepG2, PLK1 transcripts and protein were
significantly reduced, whereas in Hep3B, PLK1 transcripts were
almost 4-fold higher compared to the untreated control and
protein expression was also elevated (Fig. 4c,d). Here we show that
PLK1 downregulation in response to DNA damage in p53-wild
type cells is also accompanied by promoter hypermethylation and
this hypermethylation can be induced by ROS whereas the
opposite scenario is observed for the p53 null cells.
PLK4 promoter methylation patterns also paralleled what we
have observed with PLK1, where HepG2 had a qualitative gain in
PLK4 promoter methylation (Fig. 4b) accompanied by a 6-fold
decrease in transcripts and a 40% decrease in protein expression
(Fig. 4d–f). This is in direct opposition to what we observed in
Hep3B cells, which had no observable gain of methylation for
PLK4, but more importantly, there was an increase in transcripts
and protein by 5-fold and 30% respectively compared to the
untreated cells (fig. 4d,e).
This data indicates that PLK1 and PLK4 promoter methylation
is p53-dependent and that ROS may play an important role in the
regulation of both of these genes. This correlates with recent work
by Nakamura et al. which determined that under stress and DNA
damage in colorectal cells, PLK4 is initially activated, but its
expression is abrogated over time in p53-wild type cells followed
by an increase in p53 levels. In p53-null cells, PLK4 protein levels
persisted over the same period of time [37].
Previous examination of PLK2 expression has shown that it can
be induced by p53 during DNA damage and stress via p53 directly
biding to its consensus sequence within the PLK2 promoter
[43,44]. More recently, PLK2 transcript levels have been used as
predictors in determining the genotoxicity of potential hepatocarcinogens [45]. So, it was not surprising to see that post ROS
treatment of HepG2 cells, PLK2 lost promoter methylation (Fig. 4b)
along with a 2-fold increase in PLK2 transcript (Fig. 4g) and
protein levels (Fig. 4d). In Hep3B cells, PLK2 displayed a gain of
methylation at its promoter region after ROS exposure (Fig. 4b),
correlated with decreased protein levels, suggesting that in the
absence of p53, the PLK2 promoter region becomes hypermethylated in HCC in the presence of ROS (Fig. 4d).
PLK3 activity is also known to become upregulated in the
presence of H2O2. This increase in activity leads to the
phosphorylation of p53 at serine 20 in human fibroblast cells
[31]. Therefore, we would expect PLK3 levels to increase in
response to ROS treatment. Although PLK3 promoter methylation
remained largely unchanged between the untreated and the ROS
exposed cells (Fig. 4b), PLK3 transcripts (Fig. 4h) and protein levels
(Fig. 4d) were elevated in ROS treated HepG2 cells. However, in
the absence of p53, PLK3 transcripts and protein levels were not
significantly changed with ROS treatment (Fig. 4h,d).
5
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Figure 3. Hypoxia-induced modification of PLK promoter methylation in HCC cells. (a) Promoter methylation status of the plks examined
in HCC-derived cells HepG2 and Hep3B; U = unmethylated, M = methylated. Fully methylated HeLa DNA was used as a positive control (+M), no
template was added to the negative control (2M). (b) Post hypoxia, PLK4 transcripts were assessed via qPCR in RNA extracted from HCC cells. All
qPCR data is representative of the mean value of three independent experiments and error bars represent +/2 SD. (c) PLK protein levels were
examined post treatment from whole cell lysates. Actin was used as a loading control. (2) represents lysates from untreated cells, (+) lysates from
cells grown in the presence of hypoxia. (d) Quantification of protein levels using densitometry. Levels have been normalized to the respective
untreated controls. Data is representative of the mean value of three independent experiments and error bars represent +/2 SD. (e) The fold change
of PLK1 transcripts as determined by qPCR. Values normalized to the respective untreated sample. (f) PLK2 and PLK3 analyzed and fold changed
determine by normalization to the respective untreated samples. (g) Hif1a transcripts post hypoxia were determine by real-time PCR using a Taqman
probe.
doi:10.1371/journal.pone.0087918.g003

tions specific to tissue or cell type? Previous literature suggested
that certain gene-signatures that are found in HCC cells are not
found in other cell types such as colon carcinomas [42]. We chose
to replicate our experiments with hypoxic conditions and in the
presence of ROS using osteosarcoma derived cells within the same
p53 context. We employed the p53-wild type cells U2-OS and the
p53 null cells Saos-2 [41]. First, we examined the promoter
methylation and expression of the PLKs in the sarcoma-derived
cells under hypoxic conditions. Interestingly, in osteosarcoma cells,
PLK1 promoter regions became hypomethylated in both U2-OS
and Saos-2 cells (Fig. 5a) followed by upregulation of the
accompanying transcripts and protein levels compared to the
untreated cells (Fig. 5b,c). This suggests that hypoxia-induced
modifications to the promoter methylation of PLK1 in the above
mentioned cell lines is not p53 dependent. Conversely, when
examining the PLK2 promoter methylation under hypoxic
conditions, U2-OS cells displayed a loss of promoter methylation
(Fig. 5a) followed an almost 2-fold increase in transcripts (Fig. 5d),

Here we show that in HCC cells, PLKs 1,2, and 4 become
epigenetically modified in the presence of ROS, and that this
regulation is in part, p53 dependent. Moreover, in Hep3B cells,
which lack p53, the upregulation of the PLKs needed for DNA
damage repair, PLK2 and PLK3, are impaired in the presence of
ROS. This is also accompanied by an increase in PLK1 and PLK4
in p53 null cells. In the clinical setting, PLK1 and PLK4 have been
found to be jointly upregulated in colorectal cancers compared to
the normal mucosa in almost 80% of the cases examined [4].
Furthermore, upregulation of PLK4 leads to centrosome amplification and multipolar spindle formation resulting in aneuploidy,
which is a signature of many solid tumours [46]. In addition, it is
important to note that more than 50% of colorectal cancers
harbour p53 mutations [47].

Plk promoter methylation in osteosarcoma-derived cells
These results raised the question whether these modifications
were a general phenomenon or were these epigenetic modifica-

PLOS ONE | www.plosone.org
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Figure 4. Modification of PLK promoter methylation marks in HCC cells exposed to ROS. (a) A p53 activity assay was performed to confirm
activation of p53 with genotoxic stress caused by ROS. The percent activity is the average of three independent experiments with error bars
representing the +/2 SD. (b) MSP analysis of plk promoter methylation; U = unmethylated, M = methylated. Fully methylated HeLa DNA was used as a
positive control (+M), no template was added to the negative control (2M). (c) Plk1 transcript levels were examined and normalized to the respective
untreated samples. All qPCR data is representative of the mean value of three independent experiments and are normalized to the untreated
samples. Error bars represent +/2 SD. (d) Western blot analysis of PLK protein levels. Actin was used as a loading control. (2) represents the lysates
from untreated cells, (+) lysates from cells were grown in the presence of ROS. (e) The fold change in plk4 transcripts from cells exposed to ROS. (f)
Quantification of PLK4 protein levels. Data is representative of three independent experiments and the error bars represent +/2 SD. * denotes
significance with a p,0.05. (g,h) PLK2 and PLK3 change in transcripts as determined by real time PCR.
doi:10.1371/journal.pone.0087918.g004

U2-OS, the PLK4 promoter region was initially methylated prior
to treatment, but with hypoxia treatment, there was a loss of
detectable methylation, though this did not translate into
significant changes at the transcript or protein levels (Fig. 5a,g–
i). The examination of sarcoma cells illustrates that hypoxia can
differentially impact the PLK promoter methylation patterns
between cell types, and that p53 may not have the same impact
on the epigenetic regulation of the PLKs in all cells. HIF1a
transcript levels were examined and were found to be elevated by
1.5–2 fold in both cell types (Figure S2a).
ROS treatment of sarcoma cells resulted in very different
pattern of methylation than that seen in HCC cell lines.
Confirmation of ROS-induced increased in p53 activity was
carried out via Western blot analysis and with a p53 activity assay,
which showed an increase in p53 activity in U2-OS cells by almost
9-fold, whereas no change was detected with SAOS-2 (Figure
S2b,c). Unlike HCC cells, in both osteosarcoma cell lines, PLK2

while a only a slight change in protein level was observed (Fig. 5c);
Saos-2 cells on the other hand, had no distinct change in promoter
methylation (Fig. 5a), however, qPCR analysis revealed a decrease
in PLK2 transcripts by almost 5-fold resulting in a slight decrease in
protein (Fig. 5c,d). A study by Matthew et al. revealed that PLK2
has an active and p53-dependent role in the cellular response to
hypoxia by indirectly restraining the mTOR signaling pathway
during hypoxia, so it was expected that we would see an increase
in PLK2 in U2-OS and not Saos-2 [48]. When examining the
remaining PLKs, PLK3’s promoter region did not appear to change
in response to hypoxia, in either cell type and transcript and
protein levels did not differ from the untreated (Fig. 5a,e,f), similar
to what we have seen in the MEFs and HCC cells. In Saos-2 cells,
the PLK4 promoter region became hypermethylated in the
presence of hypoxia (Fig. 5a) followed by a decrease in PLK4
transcripts by nearly 4-fold compared to the untreated (Fig. 5g),
which resulted in a moderate decrease in protein levels (Fig. 5h). In
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Figure 5. Examination of PLK promoter methylation in sarcoma-derived cells grown in the presence of oxidative stress. (a) PLK
promoter methylation was determined by methylation-specific PCR; U = unmethylated, M = methylated. Fully methylated HeLa DNA was used as a
positive control (+M), no template was added to the negative control (2M). (b) Fold change in plk1 transcripts. All qPCR values have been normalized
to the respective untreated samples. Here the mean value of three independent experiments are depicted with error bars representing the +/2 SD.
(c) PLK1 and PLK2 protein levels in U2-OS and SAOS-2 cells treated with hypoxia and ROS. GAPDH was used as a loading control. (2) indicates lysates
extracted from untreated samples, (+) represents lysates extracted from cells exposed to either hypoxia or ROS. (d,e) PLK2 and PLK3 transcripts as
determined by qPCR. ND = not detectable. (g) Transcript changes for PLK4 in cells exposed to ROS and hypoxia. (h) PLK4 protein levels in sarcoma
cells treated with hypoxia and ROS (+) compared to the untreated counterpart (2). GAPDH was used as a loading control. (i) PLK4 protein levels
quantified with densitometry analysis of the Western blot images. The histogram is representative of the mean from three independent experiments
with error bars showing the +/2 SD. * denotes significance with a p,0.05.
doi:10.1371/journal.pone.0087918.g005

the untreated, similar to the response observed in HCC cells
(Fig. 5h,i). This suggests that regardless of cell type, PLK4
continues to be sensitive to ROS-induced promoter hypermethylation within a functional p53 context.

became hypermethylated (fig. 5a) accompanied by undetectable
transcripts and significantly decreased protein levels (Fig. 5c,d).
Although PLK3 promoter methylation did not increase with
treatment, transcripts and protein levels were also undetectable in
either cell type (Fig. 5e,f). This suggests that PLK2 and PLK3 are
differentially regulated in osteosarcoma cell lines compared to
HCC cell lines. The PLK1 promoter region also did not display a
change in promoter methylation, remaining hypermethylated in
both cell lines similar to our observations in HCC and MEFs
(Fig. 5a). Real-time PCR did reveal a slight decrease in PLK1
transcripts (Fig. 5b) and protein levels in SAOS-2 cells, but not in
U2-OS cells (Fig. 5c). However, when examining PLK4, we
noticed a dramatic loss of promoter methylation in Saos-2 cells in
response to ROS, but not in U2-OS cells (Fig. 5a). Along with
promoter hypomethylation in Saos-2 there was a minor increase in
transcripts (Fig. 5a, g). PLK4 protein levels were also elevated in
treated Saos-2 cells by more than a 10%; whereas U2-OS cells
displayed a decrease in PLK4 protein by almost 20% compared to
PLOS ONE | www.plosone.org

Global methylation and DNMT levels
In general, cells exposed to oxidative stress also experience shifts
in global methylation patterns that can be associated with
modifications to local methylation patterns at gene promoter
regions [49,50]. As part of our epigenetic analysis of the Plks, we
wanted to determine if the modifications we observed at Plkspecific promoter regions were associated with a general increase
in global methylation and whether any change varied between p53
wild type and p53 null cells. Here we examined the whole genome
methylation of DNA from cells subjected to either ROS or
hypoxia treatment. With hypoxia, both Plk4 wild type and
heterozygous MEFs had a slight decrease in global methylation
compared to the untreated samples by approximately 15%
8
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(Fig. 6d). It was previously reported that p53 wild type and p53
null colorectal cells, post hypoxia exposure, have increased
transcript levels of DNMT3a, with a greater increase observed
in p53 null colorectal cells [52]. Also, in an in vivo study done by
Park et al., a p53 heterozygous and null mouse model revealed
elevated levels of DNMT3a compared to the wild type littermates
prior to any tumour development [53]. This suggests that
DNMT3a is deregulated in Plk4+/2 MEFs in a manner similar
to that seen in p53 null cells. This also correlates to the decrease in
p53 activity that we have observed in Plk4+/2 MEFs and reenforces the importance of the Plk4-p53 relationship and
interaction axis.
ROS treated Plk4+/2 MEFs also displayed an increase in global
methylation (Fig. 6a), similar to what we observed in the HCC and
osteosarcoma cancer cells (Fig. 6b,c). This was in contrast to global
methylation levels in the Plk4 wild type MEFs which decreased
with ROS (Fig. 6a). This once again suggests that Plk4
heterozygosity results in deregulation of the response to oxidative
stress.
The contributions to tumourigenesis are complex and multifactorial. Oxidative stress has been acknowledged as one such
contributor in the path to carcinogenesis. Previous studies have
shown that the PLKs are subject to regulation through posttranslational modifications [54,55]. Our observations here show
that the Plks, whose proper regulation is essential for cell cycle
fidelity, become deregulated in the presence of both hypoxia and

(Fig. 6a). This is similar to what Shahrzad et al. demonstrated in
melanoma cells, under anoxia, global methylation decreased
between 15–20% [49]. We also observed a similar trend with
HCC and osteosarcoma cells, with a 15–40% decrease in global
methylation (Fig. 6b,c). There was little difference in global
methylation between the hypoxia treated p53 wild type and p53
null cells although, in three independent experiments, Hep3B cells
displayed a greater loss of global methylation in comparison to
HepG2 (Fig. 6b). DNA methylation is maintained by DNA
methyltransferases (DNMTs) which are enzymes that catalyze the
transfer of methyl groups to cytosines which are 59 to guanine
[51]. DNMT1 is responsible for maintenance methylation during
replication, and DNMT3a and DNMT3b drive de novo methylation [51]. It was therefore of interest to determine whether the
changes in global methylation were also accompanied by
differences in protein levels of the DNMTs.
DNMT1 and 3b protein levels have both been shown to
become downregulated with hypoxia along with a decrease in
DNMT activity which would lead to an overall decrease in global
methylation marks [52]. We examined the levels of the DNMT’s
in both wild type and Plk4 heterozygous MEFs and found that this
was also the case, where DNMT1 and DNMT3b protein levels
decreased with hypoxia (Fig. 6d). When examining DNMT3a,
protein levels were elevated in Plk4 heterozygous MEFs prior to
treatment and remained elevated post hypoxia treatment, but the
wild type MEFs did not display this change in DNMT3a levels

Figure 6. Analysis of global methylation in MEFs, HCC and osteosarcoma cells and DNMTs levels in MEFs. An ELISA-based global
methylation assay was performed to determine changes in global methylation levels due to oxidative stress as a result of hypoxia and ROS exposure.
The histograms are representative of three independent experiments and the error bars depict the +/2 SD. (a) In MEFs the values have been
normalized to the untreated wild-type cells. (b,c) The values have been normalized to the respective untreated samples. (d) Western blot analysis was
used to determine the levels of the DNMTs from whole cell lysates extracted from untreated (2) and treated (+) MEF cells.
doi:10.1371/journal.pone.0087918.g006
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contributor to carcinogenesis [1,8–11]. Currently, PLK1 has been
the most targeted PLK for drug development [56–58], however,
promoter hypermethylation is a reversible phenomenon for which
there are drugs already in clinical use [59] that could be used as
prophylactic agents or could help reverse hypermethylationinduced downregulation of the remaining four tumour suppressing
PLKs in combination with traditional therapies.

ROS through epigenetic modifications to their respective
promoter regions. However, the deregulation that we have
observed is cell-specific, resulting in methylation patterns that
are similar, like those between MEFs and HCC, and patterns that
differ like those observed in sarcoma-derived cells. The promoter
methylation of PLK4 is also correlated with the status of p53 in the
cell. Plk4 haploinsufficiency, together with oxidative stress-induced
epigenetic deregulation can inadvertently lead to the upregulation
of Plk1. Based on our observation and the current literature, we
propose a model in which p53 likely leads to downregulation of
transcription for PLK1 and PLK4 in the presence of cellular stress
by either recruiting or cooperating with DNMT1, DNMT3a and/
or histone deacetylases (HDACs); this leads to an increase in
promoter hypermethylation and hence changes in expression [36–
40] (Fig. 7a). In the absence of p53, cellular stress would lead to the
upregulation of pro-mitotic PLKs (PLK1 and PLK4) resulting in a
push through the G2/M checkpoint that would contribute to
genomic instability and tumourigenesis (Fig. 7b)
The methylation status of the PLKs could also be used as an
indicator of oxidative stress at the cellular level. These modifications to PLK epigenetic marks may even be an early event in the
multi-stage process leading to tumourigenesis, given that we have
observed detectable changes 18 hours post-treatment. Furthermore, promoter hypermethylation of the PLKs is a common event
in a variety of cancers, including blood neoplasms, hepatocellular
carcinoma, and ovarian cancer. Aberrant promoter methylation,
induced specifically via microenvironemtal cues, could be another

Materials and Methods
Ethics Statement
All animal procedures were carried out in accordance with
animal care protocols approved by the University of Windsor
Animal Care Committee under the guidelines of the Canadian
Council on Animal Care.

Tissue Culture
Mouse embryonic fibroblasts (MEFs) were harvested from
Plk4+/+ and Plk4+/2 embryos at day 12.5 post coitus, as described in
Ko et al, 2005 [2]. The procedure was carried out in accordance
with animal care protocols approved by the University of Windsor
Animal Care Committee under the guidelines of the Canadian
Council on Animal Care. The MEFs were maintained in DMEM
supplemented with 20% fetal bovine serum and 1% penicillin G
sodium/streptomycin sulphate at 10,000 ug/mL, and 0.5%
gentamycin 10 mg/mL. Cell lines were purchased from ATCC,
U2-OS and Saos-2 cells were maintained in McCoy’s media

Figure 7. A potential role for p53 in the silencing of the PLKs as a result of oxidative stress. Previous data has established that p53 can
regulate both PLK1 and PLK4 expression through protein-protein interactions. Here we have incorporated our observations into the known
mechanisms of the p53-PLK regulatory axis (a.) Our data suggests that when oxidative stress upregulates p53 activity, this can lead to downstream
effects that can potentially induce the epigenetic silencing of the PLKs. In wild type p53 cells, these mechanisms can include the recruitment and/or
collaboration with epigenetic modifiers such as DNMT1, DNMT3a or histone deacetylases (HDACs). (b) However, oxidative stress in the absence of
p53, these vital inhibitory interactions carried out through the p53 pathway are abolished. PLK1 and PLK4 expression thus carries on unhindered,
potentially pushing the cell through the G2/M transition point with unrepaired DNA damage, resulting in genomic instability and aneuploidy, both of
which are hallmarks of cancer.
doi:10.1371/journal.pone.0087918.g007
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supplemented with 10% FBS. Hep3G2 and Hep3B cell lines were
grown in MEM with 10% FBS. All the cell lines were kept in a
37uC incubator with 5% CO2. During hypoxic treatment, cells
were grown in a hypoxia incubator chamber (STEMCELL
Technologies Inc.) flooded with 2% CO2 at a rate of 10 L/min
for 8 minutes then incubated for 18 hours at 37uC. Reactive
oxygen species were generated using 200 um H2O2 for 18 hours;
treated cells were grown in standard culture conditions.

p53 activity assay
The Human/Mouse Active p53 DuoSetH IC (R&D Systems)
assay was carried out according to the manufacturer’s protocol.
Briefly, cells were grown to 80–90% confluence and the nuclear
fraction of protein was extracted and sandwich ELISA assay was
used to determine p53 activity.

Global methylation assay
The global methylation of genomic DNA was determined by
using 100 ng of ProK extracted gDNA in a sandwich ELISA
colourimetric assay (Epigentek). The assay was carried out
according to manufacturer’s instructions.

Methylation Specific PCR
DNA was extracted from cells prior and post treatment using
ProK digestion buffer (0.5 mg/mL) followed by phenol chloroform extraction. Genomic DNA was subjected to bisulfite
conversion as described in Herman et al. [60]. Post-bisulfite
treatment, the DNA was purified using the Wizard mini DNA
clean-up kit (Promega), desulfanated with NaOH and ethanol
precipitated. MSP was performed with primers designed for
individual Plks using the MethPrimer program [61]. For sequences
please see Ward et al. [10]. Positive controls of fully methylated
NIH 3T3 mouse DNA and HeLa human DNA (NEB) were also
included in all experiments.

Statistical analysis
All Western blot analysis, transcript levels, and global methylation assays are represented as the mean +/2 standard deviation.
These data were evaluated using Statsoft Statistica software
version 7.1 using One-way ANOVA analysis. Significance
represents a p,0.05. All results are representative of three
independent experiments.

Supporting Information
Western blot analysis

Figure S1 Assessment of plk2 and plk3 levels in treated
MEFs and p53 levels in HCC cells. (a) Methylation status of
Plk2 in treated MEFs was determined by MSP. (b) Western blot
analysis of Plk2 and Plk3 protein in untreated (2) and treated (+)
MEFs. GAPDH was used as a loading control. (c) p53 protein
levels determine via Western blot analysis in untreated (2) and
treated (+) HCC cells. GAPDH was used as a loading control.
(PPTX)

Whole cell lysates were extracted using a lysis buffer (50 mM
Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X)
with an EDTA-free protease inhibitor cocktail (Bio Basics Inc.)
20 ug of total protein was used to perform Western blot analysis.
Primary antibodies were purchased accordingly, anti-PLK2, antiPLK3, and anti-DNMT3b (from Santa Cruz), anti-PLK1, antiPLK4, anti-GAPDH, and anti-DNMT3A (from Cell Signalling),
and anti-DNMT1 and anti-Actin (from Sigma). For secondary
antibodies, anti-rabbit (from Cell Signalling) and anti-mouse HRP
(from Sigma) were used. Bands were visualized by ECL (Thermo
Scientific) and blots were acquired on an Alpha Innotech
MultimageTM Light Cabinet and densitometry analysis was
carried out using OptiQuant software Version 5.0.

Figure S2 Examination of Hif1a transcripts along with
p53 levels and activity in treated osteosarcoma cells. (a)
Transcript levels of Hif1a were determined by qPCR and
normalized to the respective untreated samples. The histogram
is representative of the mean from three independent experiments
with errors bars showing +/2 SD. (b) p53 protein levels in
untreated (2) and treated (+) U2-OS and SAOS-2 cells. (c) The
activity of p53 pre- and post-treatment from nuclear extracts of
osteosarcoma cells. The values were normalized the respective
untreated samples. Error bars represent the +/2 SD from three
independent experiments.
(PPTX)

Real time PCR
RNA from treated cells was extracted using the RNeasyH mini
kit (Qiagen). RNA extraction was performed according to
manufacturer’s protocols. Reverse transcription was carried out
using the First Strand cDNA synthesis kit (Invitrogen) according to
manufacturer’s instructions. Real time PCRs were carried out on
an ABI 7300 machine using Taqman gene expression probes for
mouse Plk1, Plk4, and HIF1a; and human PLK1-PLK4, and HIF1a
(Applied biosystems). GAPDH was used as an internal control in
ROS qPCR, but not in hypoxia qPCR due to GAPDH transcripts
also being affected by hypoxia treatment [62]. Hypoxia transcript
values were normalized by addition of 100 ng of total cDNA to
each reaction and DCT for treated samples were calculated from
the untreated CT values as per [57]; additional calculations were
performed according to the Taqman assay manual.
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